Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer


Abacioglu U., Yumuk P. F. , Caglar H., Sengoz M., Turhal N.

BMC CANCER, cilt.5, 2005 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

Background: Combined chemoradiotherapy (CRT) is the treatment of choice for stage III NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III NSCLC.